رجوع
64
67
نطاق اليوم
KWD 8.50
KWD 9.00
نطاق 52 أسبوعًا
KWD 5.00
KWD 13.55
حجم التداول
700
متوسط 50 يوم / 200 يوم
KWD 9.74
/
KWD 11.06
الإغلاق السابق
KWD 9.00
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Healthcare (626 نظير)
| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | 5.5 | 0.4 |
| P/B | 1.5 | 2.9 |
| ROE % | 31.4 | 3.8 |
| Net Margin % | 6.7 | 3.9 |
| Rev Growth 5Y % | 29.7 | 10.0 |
| D/E | 1.8 | 0.2 |
النقاط الرئيسية
Revenue grew 29.72% annually over 5 years — strong growth
ROE of 31.41% indicates high profitability
Negative free cash flow of -8.00M
P/E of 5.52 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 4.62%
Capital efficient — spends only 8.31% of revenue on capex
النمو
Revenue Growth (5Y)
29.72%
Revenue (1Y)25.10%
Earnings (1Y)13.70%
FCF Growth (3Y)N/A
الجودة
Return on Equity
31.41%
ROIC11.16%
Net Margin6.73%
Op. Margin10.30%
الأمان
Debt / Equity
1.83
Current Ratio1.57
Interest Coverage5.42
التقييم
P/E Ratio
5.52
P/B Ratio1.52
EV/EBITDA7.19
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 25.10% | Revenue Growth (3Y) | 23.66% |
| Earnings Growth (1Y) | 13.70% | Earnings Growth (3Y) | 26.28% |
| Revenue Growth (5Y) | 29.72% | Earnings Growth (5Y) | 53.63% |
| Profitability | |||
| Revenue (TTM) | 2.47B | Net Income (TTM) | 166.00M |
| ROE | 31.41% | ROA | 6.71% |
| Gross Margin | 68.42% | Operating Margin | 10.30% |
| Net Margin | 6.73% | Free Cash Flow (TTM) | -8.00M |
| ROIC | 11.16% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 1.83 | Current Ratio | 1.57 |
| Interest Coverage | 5.42 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | 5.52 | P/B Ratio | 1.52 |
| P/S Ratio | 0.37 | PEG Ratio | 4.96 |
| EV/EBITDA | 7.19 | Dividend Yield | 0.00% |
| Market Cap | 916.19M | Enterprise Value | 1.83B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.47B | 1.97B | 1.61B | 1.22B | 871.20M |
| Net Income | 166.00M | 146.00M | 104.10M | 48.60M | 29.80M |
| EPS (Diluted) | 1.56 | 1.37 | 0.98 | 0.46 | 0.30 |
| Gross Profit | 1.69B | 1.36B | 1.09B | 787.80M | 570.20M |
| Operating Income | 254.00M | 228.50M | 154.80M | 82.30M | 60.00M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 2.47B | 2.00B | 1.69B | 1.32B | 1.15B |
| Total Liabilities | 1.87B | 1.54B | 1.39B | 1.11B | 1.01B |
| Shareholders' Equity | 603.00M | 454.00M | 297.80M | 210.60M | 139.50M |
| Total Debt | 1.10B | 791.00M | 773.30M | 628.30M | 606.70M |
| Cash & Equivalents | 195.00M | 133.00M | 161.10M | 106.80M | 197.30M |
| Current Assets | 1.08B | 813.30M | 633.40M | 487.60M | 446.00M |
| Current Liabilities | 686.00M | 630.00M | 538.80M | 425.00M | 305.90M |
درجات الاستراتيجيات
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
#111 of 616
#66 of 658
النشاط الأخير
دخل
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
دخل
Contrarian Investing (David Dreman)
Mar 24, 2026